Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: A K-CaP registry-based analysis

Jee Soo Park, Kyo Chul Koo, In Young Choi, Ji Youl Lee, Jun Hyuk Hong, Choung Soo Kim, Hyun Moo Lee, Sung Kyu Hong, Seok Soo Byun, Koon Ho Rha, Byung Ha Chung, Kwang Suk Lee

Research output: Contribution to journalArticle

Abstract

When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP), adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the final analysis were categorized based on their adverse laboratory/pathological features.Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977 (44.1%) and 634 (14.1%) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS. Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P = .976).We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for undergoing additional treatment based on OS and BCFFS.

Original languageEnglish
Pages (from-to)e17931
JournalMedicine
Volume98
Issue number45
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Prostatectomy
Registries
Survival
Prostate-Specific Antigen
Seminal Vesicles
Neoplasm Grading
Lymph Node Excision
Prostatic Neoplasms
Databases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, Jee Soo ; Koo, Kyo Chul ; Choi, In Young ; Lee, Ji Youl ; Hong, Jun Hyuk ; Kim, Choung Soo ; Lee, Hyun Moo ; Hong, Sung Kyu ; Byun, Seok Soo ; Rha, Koon Ho ; Chung, Byung Ha ; Lee, Kwang Suk. / Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy : A K-CaP registry-based analysis. In: Medicine. 2019 ; Vol. 98, No. 45. pp. e17931.
@article{ea6e5a54f83e4817afff80f4ebc877c2,
title = "Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: A K-CaP registry-based analysis",
abstract = "When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP), adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the final analysis were categorized based on their adverse laboratory/pathological features.Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977 (44.1{\%}) and 634 (14.1{\%}) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS. Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P = .976).We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for undergoing additional treatment based on OS and BCFFS.",
author = "Park, {Jee Soo} and Koo, {Kyo Chul} and Choi, {In Young} and Lee, {Ji Youl} and Hong, {Jun Hyuk} and Kim, {Choung Soo} and Lee, {Hyun Moo} and Hong, {Sung Kyu} and Byun, {Seok Soo} and Rha, {Koon Ho} and Chung, {Byung Ha} and Lee, {Kwang Suk}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/MD.0000000000017931",
language = "English",
volume = "98",
pages = "e17931",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "45",

}

Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy : A K-CaP registry-based analysis. / Park, Jee Soo; Koo, Kyo Chul; Choi, In Young; Lee, Ji Youl; Hong, Jun Hyuk; Kim, Choung Soo; Lee, Hyun Moo; Hong, Sung Kyu; Byun, Seok Soo; Rha, Koon Ho; Chung, Byung Ha; Lee, Kwang Suk.

In: Medicine, Vol. 98, No. 45, 01.11.2019, p. e17931.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy

T2 - A K-CaP registry-based analysis

AU - Park, Jee Soo

AU - Koo, Kyo Chul

AU - Choi, In Young

AU - Lee, Ji Youl

AU - Hong, Jun Hyuk

AU - Kim, Choung Soo

AU - Lee, Hyun Moo

AU - Hong, Sung Kyu

AU - Byun, Seok Soo

AU - Rha, Koon Ho

AU - Chung, Byung Ha

AU - Lee, Kwang Suk

PY - 2019/11/1

Y1 - 2019/11/1

N2 - When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP), adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the final analysis were categorized based on their adverse laboratory/pathological features.Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977 (44.1%) and 634 (14.1%) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS. Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P = .976).We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for undergoing additional treatment based on OS and BCFFS.

AB - When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP), adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the final analysis were categorized based on their adverse laboratory/pathological features.Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977 (44.1%) and 634 (14.1%) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS. Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P = .976).We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for undergoing additional treatment based on OS and BCFFS.

UR - http://www.scopus.com/inward/record.url?scp=85074721627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074721627&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000017931

DO - 10.1097/MD.0000000000017931

M3 - Article

C2 - 31702677

AN - SCOPUS:85074721627

VL - 98

SP - e17931

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 45

ER -